Development of A Risk-Based Accelerated Approval Decision Model Balancing Speed, Safety, and Evidence Quality in Pharmaceutical Regulatory Science

Accelerated approval pathways have transformed patient access to medicines for serious and lifethreatening conditions over three decades, enabling marketing authorization based on surrogate or intermediate clinical endpoints reasonably predicted to correlate with clinical benefit before confirmatory evidence is available. The social contract underlying this regulatory innovation requires timely and rigorous post-market confirmatory evidence generation in exchange for conditional early access, creating a system whose long-term legitimacy depends on the reliability of both its evidentiary basis and its post-market governance mechanisms. Despite extensive guidance from the Food and Drug Administration, the European Medicines Agency, and the World Health Organization, no validated quantitative decision model exists to systematically weigh the competing factors bearing on pathway designation appropriateness in a manner that is transparent, reproducible, and auditable across review teams and regulatory jurisdictions worldwide. This paper presents the Risk-Based Accelerated Approval Decision Model (RBAADM), a six-dimension composite scoring framework integrating disease severity and condition burden, unmet medical need, evidence quality and surrogate validity, benefit-risk profile, postmarket commitment enforceability, and regulatory system capacity into a 120-point composite index with three clearly defined pathway designation tiers: Standard Approval (0-39), Expedited Approval (40-69), and Accelerated Approval (70-120). The RBAA-DM's theoretical architecture applies the proportionality principle, under which evidence thresholds for marketing authorization should be proportionate to the balance between patient access urgency and regulatory governance capacity to manage residual uncertainty through conditional post-market mechanisms. The model was calibrated using 187 FDA and EMA regulatory decisions from 2010 to 2023. Retrospective validation against independent expert panel assessments achieved 79.1 percent overall concordance, improving to 82.7 percent following behavioral anchor revision based on systematic discordance analysis. The RBAA-DM draws on cardiovascular disease risk quantification from sub-Saharan African clinical populations, composite risk scoring methodology from fraud detection and cybersecurity regulatory compliance, industrial safety governance and environmental risk management maturity frameworks, lifecycle performance assessment evidence, digital governance and algorithmic accountability design, and healthcare policy governance. Integration into pre-submission consultation, internal regulatory review documentation, and international harmonization discussions is recommended as the priority implementation pathway for advancing pharmaceutical regulatory science globally.

Authors

Institutions

Publication Details

Journal
RESEARCH JOURNAL OF PURE SCIENCE AND TECHNOLOGY
Published
2026-11-18
DOI
https://doi.org/10.56201/rjpst.v7.no6.2024.pg120.161
Citations
23
Primary Topic
Pharmaceutical Economics and Policy
Type
article
Field-Weighted Citation Impact
45.84
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development of A Risk-Based Accelerated Approval Decision Model Balancing Speed, Safety, and Evidence Quality in Pharmaceutical Regulatory Science

Felix Ikechukwu Eze
23 citations
RESEARCH JOURNAL OF PURE SCIENCE AND TECHNOLOGY
Pharmaceutical Economics and Policy
45.84
article

Development of A Risk-Based Accelerated Approval Decision Model Balancing Speed, Safety, and Evidence Quality in Pharmaceutical Regulatory Science

Felix Ikechukwu Eze
article en
23 citations

Abstract

Accelerated approval pathways have transformed patient access to medicines for serious and lifethreatening conditions over three decades, enabling marketing authorization based on surrogate or intermediate clinical endpoints reasonably predicted to correlate with clinical benefit before confirmatory evidence is available. The social contract underlying this regulatory innovation requires timely and rigorous post-market confirmatory evidence generation in exchange for conditional early access, creating a system whose long-term legitimacy depends on the reliability of both its evidentiary basis and its post-market governance mechanisms. Despite extensive guidance from the Food and Drug Administration, the European Medicines Agency, and the World Health Organization, no validated quantitative decision model exists to systematically weigh the competing factors bearing on pathway designation appropriateness in a manner that is transparent, reproducible, and auditable across review teams and regulatory jurisdictions worldwide. This paper presents the Risk-Based Accelerated Approval Decision Model (RBAADM), a six-dimension composite scoring framework integrating disease severity and condition burden, unmet medical need, evidence quality and surrogate validity, benefit-risk profile, postmarket commitment enforceability, and regulatory system capacity into a 120-point composite index with three clearly defined pathway designation tiers: Standard Approval (0-39), Expedited Approval (40-69), and Accelerated Approval (70-120). The RBAA-DM's theoretical architecture applies the proportionality principle, under which evidence thresholds for marketing authorization should be proportionate to the balance between patient access urgency and regulatory governance capacity to manage residual uncertainty through conditional post-market mechanisms. The model was calibrated using 187 FDA and EMA regulatory decisions from 2010 to 2023. Retrospective validation against independent expert panel assessments achieved 79.1 percent overall concordance, improving to 82.7 percent following behavioral anchor revision based on systematic discordance analysis. The RBAA-DM draws on cardiovascular disease risk quantification from sub-Saharan African clinical populations, composite risk scoring methodology from fraud detection and cybersecurity regulatory compliance, industrial safety governance and environmental risk management maturity frameworks, lifecycle performance assessment evidence, digital governance and algorithmic accountability design, and healthcare policy governance. Integration into pre-submission consultation, internal regulatory review documentation, and international harmonization discussions is recommended as the priority implementation pathway for advancing pharmaceutical regulatory science globally.

RESEARCH JOURNAL OF PURE SCIENCE AND TECHNOLOGY
Syracuse University (US)
Good health and well-being
Openalex Percentile: Top 0%
Pharmaceutical Economics and Policy
45.84
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon